# US 2021/0259966 A1 · Transdermal solvent system and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0259966 A1
- Document ID: US20210259966A1
- Status: Published application
- Kind: A1
- Application number: 17/313,994
- Filed: 2021-05-06
- Published: 2021-08-26
- Earliest claimed: 2019-07-16
- Assignees: Donaghys Limited
- Applicants: Donaghys Limited
- Inventors: KAREN YERITSYAN
- Web page: https://patentgrep.com/patent/US20210259966A1

## CPC

- A61K 9/0017: {Non-human animal skin, e.g. pour-on, spot-on}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 31/429: condensed with heterocyclic ring systems
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 31/714: Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
- A61K 33/04: Sulfur, selenium or tellurium; Compounds thereof
- A61K 45/00: Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K 47/08: containing oxygen, {e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61P 33/10: Anthelmintics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described herein are transdermal solvent systems comprising at least one active agent in solution in a base solution, the base solution comprising at least one fatty acid ester compound, at least one monoterpene compound and a co-solvent in the form of DMSO or DMI and at least one plant oil. The base solution was found to be highly versatile and provide superior or at least comparable skin penetration efficacy and active agent compatibility. Methods of treatment, uses of the solvent system and methods of manufacture are also described.

## Claims

### Claim 1

(canceled)

### Claim 2

(canceled)

### Claim 3

(canceled)

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9

A base solution formulated to carry, in solution, at least one active agent and to deliver the at least one active agent via transdermal administration, the base solution comprising:
10-20% by weight of at least one fatty acid ester compound;
1-14.99% by weight of at least one monoterpene compound;
8-25% by weight dimethylsulfoxide (DMSO) and/or dimethyl isosorbide (DMI);
0.75-5% by weight of at least one plant oil;
0.1-25% by weight of at least one amphiphilic compound;
5-20% by weight at least one compound with emollient and/or humectant properties;
5-10% by weight at least one compound that acts is a wetting agent and/or emulsifier;
and
at least one ethylene glycol ether compound as a diluent added to volume q.s.

### Claim 10 (depends on 9)

The base solution as claimed in claim 9, wherein the base solution is anhydrous.

### Claim 11 (depends on 9)

The base solution as claimed in claim 9, wherein the at least one plant oil is selected from: chamomile oil, frangipani oil, lilac oil, sage oil, seabuckthorn oil, and combinations thereof

### Claim 12 (depends on 9)

The base solution as claimed in claim 9, wherein the at least one amphiphilic compound is lecithin.

### Claim 13 (depends on 9)

The base solution as claimed in claim 9, wherein viscosity of the base solution is less than or equal to 5000 cP.

### Claim 14 (depends on 9)

The base solution as claimed in claim 9, wherein the base solution further comprises at least one excipient selected from compounds with: emollient and/or humectant activity, diluents, surfactants/wetting agents, and antioxidants.

### Claim 15 (depends on 9)

A method of treating a non-human mammal, comprising topically administering a solvent system comprising the base solution as claimed in claim 9 and a therapeutically effective amount of at least one active agent dissolved in the base solution to the non-human mammal in need thereof.

### Claim 16 (depends on 9)

A method of using a solvent system in manufacturing a medicament for:
designing drugs and/or supplements; and/or
treating parasites and/or diseases; and/or
treating nutrient deficiencies,
to an animal in need thereof,
the solvent system comprising a therapeutically effective amount of at least one active agent dissolved in the base solution as claimed in claim 9.

### Claim 17 (depends on 9)

A method of manufacturing a solvent system comprising a therapeutically effective amount of at least one active agent dissolved in a base solution, the solvent system formulated for transdermal administration, the method comprising:
preparing the base solution as claimed in claim 9
selecting at least one active agent;
optionally, solubilising the at least one active agent;
adding the at least one active agent to the prepared base solution;
mixing the base solution and at least one active agent until the at least one active agent dissolves into the base solution to form the solvent system; and
optionally, adding one or more preservatives, penetrating agents, diluents, amphiphilic compounds, emollients/humectants and/or wetting agent/emulsifiers.

### Claim 18 (depends on 9)

The base solution of claim 9, wherein the at least one active agent is fully dissolved in the base solution.

### Claim 19 (depends on 9)

The base solution as claimed in claim 9, wherein the at least one fatty acid ester compound is selected from: isopropyl myristate, isopropyl palmitate, octyl dodecyl myristate, ethylhexyl stearate, glyceryl stearate, myristil myristate, stearyl stearate, cholesteryl isostearate, and combinations thereof.

### Claim 20 (depends on 9)

The base solution as claimed in claim 9, wherein the at least one monoterpene compound is selected from: camphor, eucalyptol, D-limonene, P-cymem, citranellol, and combinations thereof.
